蒙泰高新(300876.SZ)入選第三批專精特新“小巨人”企業名單
格隆匯9月14日丨蒙泰高新(300876.SZ)公佈,根據中華人民共和國工業和信息化部中小企業局發佈的《關於第三批專精特新“小巨人”企業名單的公示》,公司入選第三批專精特新“小巨人”企業名單。
公司是一家專業從事聚丙烯纖維研發、生產和銷售的高新技術企業。根據中國化學纖維工業協會的統計,公司近四年來在國內丙綸長絲行業中的產量、市場佔有率均排名第一。
公司此次榮獲第三批專精特新“小巨人”企業稱號,有利於提高公司品牌知名度,增強公司核心競爭能力,助力公司進一步創新發展,對公司的整體業務發展將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.